Alzheimer’s May Be Cyberonics’ New Frontier; Trial Costs Projected
This article was originally published in The Gray Sheet
Executive Summary
Future indications for Cyberonics' vagus nerve stimulation therapy may include Alzheimer's disease, chronic migraines and anxiety, although a decision on which to pursue first in pivotal trials awaits FDA approval for depression, the firm says
You may also be interested in...
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md
Cyberonics Expects VNS Will Capture 4% Of U.S. Depression Market By 2010
Cyberonics anticipates FDA approval of a depression indication for its VNS Therapy vagus nerve stimulation system by October 2004
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.